10-Q: ProtoKinetix Reports First Quarter 2024 Results, Net Loss of $92,026

ProtoKinetix, a development stage company, reported a net loss of $92,026 for the first quarter of 2024, with ongoing efforts to secure additional funding for research and development.

Summary

• ProtoKinetix, a development stage company, reported a net loss of $92,026 for the three months ended March 31, 2024, compared to a net loss of $107,038 for the same period in 2023.
• The company's operating expenses included $11,317 in amortization of intangible assets, $14,125 in general and administrative costs, $29,959 in professional fees, and $36,625 in research and development expenses.
• The company's cash balance decreased from $20,408 at the end of 2023 to $2,836 as of March 31, 2024.
• ProtoKinetix had a negative working capital of $(63,683) as of March 31, 2024, and will require additional financing to meet its business objectives.
• The company issued 4,166,667 shares of common stock through private placements, raising $50,000 during the quarter.
• The company is focused on the commercial validation of its AAGP molecule and is seeking research partners and financial backing.

Sentiment

Score: 4

Explanation: The document highlights a net loss and a precarious financial situation, with a very low cash balance and negative working capital. While there are some positive aspects, such as reduced expenses and private placement funding, the overall sentiment is negative due to the company's dependence on future capital raises and the lack of a commercially viable product.

Positives

• The net loss decreased by $15,012 compared to the same quarter last year.
• General and administrative expenses were significantly reduced, indicating cost-cutting measures.
• The company successfully raised $50,000 through private placements.
• The company is actively seeking research partners and financial backing to advance its AAGP molecule.

Negatives

• The company's cash balance is very low at $2,836.
• The company has a negative working capital of $(63,683).
• The company has a history of losses and has not generated significant revenue.
• The company is dependent on raising additional capital to continue operations.
• The company's disclosure controls and procedures are not effective.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional working capital.
• The company has not developed a commercially viable product and has not generated significant revenue.
• The company's stock price is volatile, which could impact its ability to raise capital.
• The company's disclosure controls and procedures are not effective, which could lead to errors in financial reporting.
• The company faces risks related to competition, intellectual property, and the ability to retain key personnel.

Future Outlook

The company intends to fund its operations by selling common stock and is actively seeking research partners and financial backing to advance its AAGP molecule. The company's future results depend on various risks and uncertainties, including the ability to obtain additional funding.

Management Comments

• Management is presently engaged in seeking additional working capital through equity financing or related party loans.
• The company is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP to market.
• The company continues to pursue research partners for cost sharing and engages institutes with grants available for continued studies on our patented AAGP molecule.

Industry Context

ProtoKinetix operates in the biotechnology sector, focusing on the development of novel therapeutics. The company's research into AAGP is aimed at addressing large markets such as targeted health care solutions. The company is competing with other biotechnology firms in the development of new treatments and therapies.

Comparison to Industry Standards

• ProtoKinetix is a development stage company, which means it is not yet generating revenue from product sales, which is common for companies in this stage of development.
• The company's negative working capital and low cash balance are concerning and indicate a need for immediate capital infusion, which is not uncommon for early-stage biotech companies.
• Compared to established biotech companies with commercialized products, ProtoKinetix is in a much earlier stage of development and faces significant financial and operational challenges.
• Many biotech companies at this stage rely heavily on private placements and grants to fund their research and development, similar to ProtoKinetix.
• The company's focus on a specific molecule (AAGP) is a common strategy in the biotech industry, where companies often specialize in a particular area of research.

Related Party Transactions

• A total of $15,000 was paid or accrued to the Company's CFO for consulting services.
• The Company reimbursed a company controlled by the CFO a total of $1,500 in office rent.
• As at March 31, 2024, there were $2,500 balances owing to related parties.

Stakeholder Impact

• Shareholders face the risk of further dilution due to the company's need to raise capital.
• Employees may be concerned about the company's financial stability and its ability to continue operations.
• Customers and suppliers are not directly impacted at this stage as the company is still in the research and development phase.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company will continue to seek additional working capital through equity financing or related party loans.
• The company will continue to pursue research partners for cost sharing and engage institutes with grants available for continued studies on its patented AAGP molecule.
• The company will continue to work with researchers, business leaders, advisors, and commercial entities to bring AAGP to market.

Key Dates

Keywords

AAGP, Antifreeze Glycoproteins, Biotechnology, Research and Development, Private Placement, Intangible Assets, Going Concern, Financial Statements, Net Loss, Working Capital